The sodium-glucose cotransporter 2 inhibitor luseogliflozin can suppress muscle atrophy in Db/Db mice by suppressing the expression of

We investigated the effect of the sodium glucose cotransporter-2 inhibitor (SGLT-2i) luseogliflozin on skeletal muscle. Eight-week-old mice were fed a standard diet or the standard diet with added luseogliflozin for 8 weeks. The mice were divided into the following four genotype/dietary groups: Db/m mice without SGLT-2i, Db/m mice with SGLT-2i inhibitor, Db/Db without SGLT-2i, and Db/Db with SGLT-2i. Among the mice with and without SGLT-2i, the ratio of soleus and plantaris muscle to body weight in the Db/Db mice was significantly lower than that in the Db/m mice. The cross-sectional area of soleus muscle in the Db/Db mice without SGLT-2i was significantly higher than that in the Db/Db mice with SGLT-2i. The expression of

Déclaration de conflit d'intérêts

Y. Hashimoto received grants from the Fuji Foundation for Protein Research, outside the submitted work. M. Fukui reports grants from AstraZeneca, grants from Astellas Pharma, grants from Nippon Boehringer Ingelheim, grants from Daiichi Sankyo Co., grants from Eli Lilly Japan, grants from Kyowa Hakko Kirin Co., grants from Kissei Pharmaceutical Co., grants from MSD, grants from Mitsubishi Tanabe Pharma Corp., grants from Novo Nordisk Pharma, grants from Sanwa Kagaku Kenkyusho Co., grants from Sanofi, grants from Ono Pharmaceutical Co., and grants from Takeda Pharmaceutical Co., outside the submitted work. The sponsors were not involved in the study design; in the collection, analysis, interpretation of data; in the writing of this manuscript; or in the decision to submit the article for publication. The authors, their immediate families, and any research foundations with which they are affiliated have not received any financial payments or other benefits from any commercial entity related to the subject of this article. The authors declare that although they are affiliated with a department that is supported financially by pharmaceutical company, the authors received no current funding for this study and this does not alter their adherence to all the journal policies on sharing data and materials. The other authors have nothing to disclose.